MEDIBIOFARMA ANNOUNCES FIRST SUBJECT DOSED IN MBF-015 PHASE I CLINICAL STUDY: New HDAC1/2 inhibitor in healthy volunteers

Navarra – July 2021– Medibiofarma S.L., a clinical-stage biotechnology company developing, as part of its portfolio of projects, a new disease-modifying therapy for the treatment of neurodegeneration and cognitive decline today announced the first subject dosed in the Phase 1 clinical trial of MBF-015. The objectives of the trial are the preliminary evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of MBF-015 after oral intake in healthy volunteers

The release as fetched from its publisher. medibiofarma.com ↗